Charles Zhu
Stock Analyst at Guggenheim
(2.58)
# 1,536
Out of 5,178 analysts
19
Total ratings
47.06%
Success rate
20.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $19.86 | -39.58% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $13.50 | +62.96% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.18 | +277.36% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $98.06 | -42.89% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.19 | +323.89% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $36.87 | -29.48% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $32.09 | -0.28% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $24.69 | -43.30% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $19.86
Upside: -39.58%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $13.50
Upside: +62.96%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.18
Upside: +277.36%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $98.06
Upside: -42.89%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.19
Upside: +323.89%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $36.87
Upside: -29.48%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $32.09
Upside: -0.28%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $24.69
Upside: -43.30%